Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately bullish: Nine analysts rate Enliven Therapeutics a consensus “Moderate Buy,” with eight buy ratings and one sell rating. The average 12-month price target is $75, above the stock’s reported $59.37 price.
• Insiders have been selling shares: Company insiders sold 186,849 shares worth approximately $11 million over the past 90 days, while insiders retain a 3% ownership stake. The reported transactions were conducted under pre-arranged Rule 10b5-1 plans.
• The stock has risen sharply but remains unprofitable: ELVN traded near its 52-week high of $62.32 and is up from a low of $14.78. The company reported a quarterly loss of $0.49 per share, missing the $0.39 loss analysts expected.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $75.00.

Several brokerages recently weighed in on ELVN. JonesTrading lifted their price objective on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a research report on Monday, June 29th. Wall Street Zen cut Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Mizuho increased their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. HC Wainwright raised their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, July 9th. Finally, Barclays began coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an "overweight" rating and a $78.00 price target for the company.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44. Following the sale, the chief financial officer owned 40,036 shares of the company's stock, valued at $2,345,308.88. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares of the company's stock, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 186,849 shares of company stock valued at $10,998,857. Company insiders own 3.00% of the company's stock.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its stake in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company's stock valued at $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its position in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after acquiring an additional 930 shares in the last quarter. KBC Group NV bought a new stake in Enliven Therapeutics in the first quarter worth about $38,000. Swiss National Bank lifted its holdings in Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company's stock valued at $990,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Up 0.1%

Shares of NASDAQ:ELVN opened at $59.37 on Wednesday. The company has a market cap of $4.35 billion, a PE ratio of -35.55 and a beta of 0.30. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The firm has a 50-day simple moving average of $56.00 and a 200 day simple moving average of $44.77.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). As a group, research analysts forecast that Enliven Therapeutics will post -1.69 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.